David Devigne

PanTera aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers by Targeted RadioTherapy (TRT). By working towards this large-scale production, PanTera’s ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general.

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate®. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling expertise and capabilities, robust assays, and high-throughput screening possibilities forms the core of our contribution. Our offering varies from long-term drug discovery partnerships, (custom) model & assay development services compound screening, to off-the-shelf products. For more information, visit: www.mimetas.com.

MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition Biosciences in the development of microbiome-based therapeutics for metabolic diseases. MRM Healths proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by life science investors Boehringer Ingelheim Venture Fund, M Ventures and the Flemish investment company PMV, together with CD3 and KU Leuven Gemma Frisius Fonds.

As fast-spreading viral diseases are a constant threat to the livestock industry, ViroVet’s team of researchers and unique network of academic and industrial partners will deliver products to reduce the impact of these diseases by providing innovative virus control solutions to secure and improve the health and value of livestock.

Aphea.Bio is dedicated to food security and ensuring a safe and healthy food chain. We aim to provide novel, science-based solutions to build the agriculture of the future: sustainable, reliable and profitable. Located in Gent, Belgium, we have a highly dedicated and qualified team of scientist and industry experts. Based on our unique high throughput R&D platform utilizing the untapped microbial space, we have been able to build a broad pipeline based on naturally occurring micro-organisms. Our solutions range from biostimulants to biocontrol, and focus mainly on row crops. Our key strength is flexibility, which allows us to quickly adapt to market needs and to provide tailored solutions. We believe that with a fresh and sincere spirit of innovation, result-driven science, and the courage to go off the beaten track, there is fertile ground to develop efficacious biological solutions to help complement or partially replace products in the major chemical indications.

PharmaFluidics is a young, dynamic & fast paced tech company based in Ghent, Belgium. As a spin-off of the Vrije Universiteit Brussels, and backed by experienced Venture Capital (Qbic, PMV, Innovation Fund/Essencia, Theodorus), PharmaFluidics has developed a series of game-changing chromatography products. With unprecedented analytical resolution performance, PharmaFluidics’ micro-chip based chromatography cartridges are now being commercialized for cutting-edge bio-marker, diagnostics and drug research & development applications in the global biotech and pharma industries. The key expertise of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence and pioneer users to develop a broad range of applications.

As fast-spreading viral diseases are a constant threat to the livestock industry, ViroVet’s team of researchers and unique network of academic and industrial partners will deliver products to reduce the impact of these diseases by providing innovative virus control solutions to secure and improve the health and value of livestock.

PanTera aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers by Targeted RadioTherapy (TRT). By working towards this large-scale production, PanTera’s ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general.

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

Our mission is to help life sciences companies accelerate drug development for improved patient outcomes, and we do this by championing the power of data. Our main product DISQOVER is an optimized search or knowledge platform which draws on semantic technology and an ontology-based knowledge graph to find links between data across databases (internal data, public data and third party data) faster and more efficiently. The platform has been developed for the pharmaceutical and biotech industries. There are thousands of health research databases, clinical trials, literature reviews, patient studies, etc. available. Before setting up a new study, scientists first need to check what kind of research has already been done – both internally and externally – on, for instance, growth hormone applications for a particular disease. In many companies, even internal information resides in hundreds of different databases, each with their own interface and search logic. As a consequence, just finding this kind of background information is a very time-consuming process. This is where DISQOVER comes in. One of the assets is that we use semantic technology to find logical but often hidden connections between internal and external data, allowing you to easily combine information from a multitude of different sources. As such, pharma and biotech companies can save valuable time and money that they can now invest in developing new medicines or treatments. Customers include: AstraZeneca, AmGen, Medidata, Prinses Máxima Institute, Aelin Therapeutics and more. DISQOVER is used amongst others by scientific researchers, bioinformaticians, and data scientists. Try DISQOVER: our community edition is always up-to-date and accessible via www.ontoforce.com (choose “try now” top right corner)

reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models. For more information please visit www.remynd.com Alternatively, please contact Koen De Witte (Managing Director - pipeline@remynd.com) to hear more about reMYND's pipeline or Bart Roucourt (Manager Contact Research - cro@remynd.com) to get more information on reMYND's Contract Research Offering.

We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate®. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling expertise and capabilities, robust assays, and high-throughput screening possibilities forms the core of our contribution. Our offering varies from long-term drug discovery partnerships, (custom) model & assay development services compound screening, to off-the-shelf products. For more information, visit: www.mimetas.com.